These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

189 related items for PubMed ID: 23534988

  • 1. Cost-utility analysis of nanoparticle albumin-bound paclitaxel versus paclitaxel in monotherapy in pretreated metastatic breast cancer in Spain.
    Alba E, Ciruelos E, López R, López-Vega JM, Lluch A, Martín M, Muñoz M, Sánchez-Rovira P, Seguí MÁ, Liria MR, Pérez-Alcántara F.
    Expert Rev Pharmacoecon Outcomes Res; 2013 Jun; 13(3):381-91. PubMed ID: 23534988
    [Abstract] [Full Text] [Related]

  • 2. nab-Paclitaxel weekly or every 3 weeks compared to standard docetaxel as first-line therapy in patients with metastatic breast cancer: an economic analysis of a prospective randomized trial.
    Dranitsaris G, Coleman R, Gradishar W.
    Breast Cancer Res Treat; 2010 Feb; 119(3):717-24. PubMed ID: 19495958
    [Abstract] [Full Text] [Related]

  • 3. Economic analysis of albumin-bound paclitaxel for the treatment of metastatic breast cancer.
    Dranitsaris G, Cottrell W, Spirovski B, Hopkins S.
    J Oncol Pharm Pract; 2009 Jun; 15(2):67-78. PubMed ID: 19036903
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. An economic evaluation of docetaxel and paclitaxel regimens in metastatic breast cancer in the UK.
    Benedict A, Cameron DA, Corson H, Jones SE.
    Pharmacoeconomics; 2009 Jun; 27(10):847-59. PubMed ID: 19803539
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Cost-utility analysis of nanoparticle albumin-bound paclitaxel (nab-paclitaxel) in combination with gemcitabine in metastatic pancreatic cancer in Spain: results of the PANCOSTABRAX study.
    Carrato A, García P, López R, Macarulla T, Rivera F, Sastre J, Gostkorzewicz J, Benedit P, Pérez-Alcántara F.
    Expert Rev Pharmacoecon Outcomes Res; 2015 Jun; 15(4):579-89. PubMed ID: 25991037
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Treatment innovations for metastatic breast cancer: nanoparticle albumin-bound (NAB) technology targeted to tumors.
    Lluch A, Alvarez I, Muñoz M, Seguí MÁ, Tusquets I, García-Estévez L.
    Crit Rev Oncol Hematol; 2014 Jan; 89(1):62-72. PubMed ID: 24071503
    [Abstract] [Full Text] [Related]

  • 13. Phase II study of weekly albumin-bound paclitaxel for patients with metastatic breast cancer heavily pretreated with taxanes.
    Blum JL, Savin MA, Edelman G, Pippen JE, Robert NJ, Geister BV, Kirby RL, Clawson A, O'Shaughnessy JA.
    Clin Breast Cancer; 2007 Dec; 7(11):850-6. PubMed ID: 18269774
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Enhancing intracellular taxane delivery: current role and perspectives of nanoparticle albumin-bound paclitaxel in the treatment of advanced breast cancer.
    Guarneri V, Dieci MV, Conte P.
    Expert Opin Pharmacother; 2012 Feb; 13(3):395-406. PubMed ID: 22263900
    [Abstract] [Full Text] [Related]

  • 18. Randomized phase II trial of weekly vs. every 2 weeks vs. every 3 weeks nanoparticle albumin-bound paclitaxel with bevacizumab as first-line chemotherapy for metastatic breast cancer.
    Seidman AD, Conlin AK, Bach A, Moynahan ME, Lake D, Forero A, Wright GS, Hackney MH, Clawson A, Norton L, Hudis CA.
    Clin Breast Cancer; 2013 Aug; 13(4):239-246.e1. PubMed ID: 23829890
    [Abstract] [Full Text] [Related]

  • 19. Management of breast cancer with nanoparticle albumin-bound (nab)-paclitaxel combination regimens: a clinical review.
    Chirgwin J, Chua SL.
    Breast; 2011 Oct; 20(5):394-406. PubMed ID: 21839635
    [Abstract] [Full Text] [Related]

  • 20. The treatment patterns, efficacy, and safety of nab (®)-paclitaxel for the treatment of metastatic breast cancer in the United States: results from health insurance claims analysis.
    Liang C, Li L, Fraser CD, Ko A, Corzo D, Enger C, Patt D.
    BMC Cancer; 2015 Dec 29; 15():1019. PubMed ID: 26714468
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.